Zacks Research Boosts Earnings Estimates for Bone Biologics

Bone Biologics Corp. (NASDAQ:BBLG) – Investment analysts at Zacks Research increased their Q3 2026 EPS estimates for shares of Bone Biologics in a research report issued to clients and investors on Wednesday, July 8th. Zacks Research analyst B. Sorensen now anticipates that the company will post earnings per share of ($0.18) for the quarter, up from their previous estimate of ($0.36). The consensus estimate for Bone Biologics’ current full-year earnings is ($1.52) per share. Zacks Research also issued estimates for Bone Biologics’ Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($1.17) EPS and FY2027 earnings at ($0.64) EPS.

Separately, Weiss Ratings upgraded Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Bone Biologics Trading Up 3.0%

NASDAQ BBLG opened at $1.38 on Friday. Bone Biologics has a 1-year low of $1.05 and a 1-year high of $4.13. The stock has a 50-day moving average of $1.32 and a 200-day moving average of $1.37. The firm has a market cap of $2.48 million, a PE ratio of -0.61 and a beta of 0.90.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43).

Institutional Investors Weigh In On Bone Biologics

A hedge fund recently raised its position in Bone Biologics stock. DRW Securities LLC raised its position in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the quarter. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. 34.30% of the stock is owned by institutional investors and hedge funds.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.